Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018220584) ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/220584 International Application No.: PCT/IB2018/053908
Publication Date: 06.12.2018 International Filing Date: 31.05.2018
IPC:
C07K 16/28 (2006.01) ,A61P 35/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
02
specific for leukemia
Applicants:
PFIZER INC. [US/US]; 235 East 42nd Street New York, New York 10017, US
Inventors:
DETTLING, Danielle Elizabeth; US
KRISHNAMOORTHY, Veena; US
POULSEN, Kristian Todd; US
SOMMER, Cesar Adolfo; US
YEUNG, Yik Andy; US
Agent:
WALDRON, Roy F.; US
Priority Data:
62/514,57402.06.2017US
62/660,90820.04.2018US
Title (EN) ANTIBODIES SPECIFIC FOR FLT3 AND THEIR USES
(FR) ANTICORPS SPÉCIFIQUES À LA FLT3 ET LEURS UTILISATIONS
Abstract:
(EN) The present invention provides antibodies that specifically bind to FLT3 (Fms- Like Tyrosine Kinase 3). The invention further provides bispecific antibodies that bind to FLT3 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of FLT3-mediated pathologies, including cancer such as Acute Myeloid Leukemia (AML).
(FR) La présente invention concerne des anticorps qui se lient spécifiquement à FLT3 (Tyrosine kinase 3 de type Fms). L'invention concerne en outre des anticorps bispécifiques qui se lient à FLT3 et à un autre antigène (par exemple, CD3). L'invention concerne également des acides nucléiques codant pour des anticorps, et des procédés permettant d'obtenir de tels anticorps (monospécifiques et bispécifiques). L'invention concerne en outre des méthodes thérapeutiques d'utilisation de ces anticorps pour le traitement de pathologies médiées par FLT3, notamment un cancer tel que la leucémie myéloïde aiguë (AML).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)